FAQs ABOUT ERLOCIP 150MG TABLET
What is ERLOCIP 150MG TABLET used for?
ERLOCIP 150MG TABLET is used in adults to treat non-small cell lung cancer at an advanced stage, as initial therapy (or as therapy if disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations), if previous chemotherapy has not helped to stop the disease and to treat cancer of the pancreas at a metastatic stage in combination with gemcitabine.
What is the mechanism of action of ERLOCIP 150MG TABLET?
ERLOCIP 150MG TABLET binds to the intracellular portion (tyrosine kinase) of the epidermal growth factor receptor (EGFR) and inhibits its activity. EGFR is expressed on the surface of both normal as well as cancer cells. Inhibition of EGFR and it’s signaling significantly decreases tumor multiplication and survival, resulting in cell death.
Can ERLOCIP 150MG TABLET be used in pregnant women?
There is no adequate data on the use of ERLOCIP 150MG TABLET in pregnant women. If you become pregnant during the treatment immediately inform your doctor who will decide if the treatment should be continued.
Can ERLOCIP 150MG TABLET be taken along with Statins?
If you are taking statins (medicines to lower your blood cholesterol), ERLOCIP 150MG TABLET may increase the risk of statin related muscle problems, which on rare occasions can lead to serious muscle breakdown (rhabdomyolysis) resulting in kidney damage, talk to your doctor before taking this medicine.
Can ERLOCIP 150MG TABLET be used in children?
ERLOCIP 150MG TABLET is not recommended for use in children and adolescents (under 18 years of age). Consult your doctor for more information on this medicine before taking it.